1. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia
- Author
-
Pouliot, Gayle P, Degar, James, Hinze, Laura, Kochupurakkal, Bose, Vo, Chau D, Burns, Melissa A, Moreau, Lisa, Ganesa, Chirag, Roderick, Justine, Peirs, Sofie, Menten, Bjorn, Loh, Mignon L, Hunger, Stephen P, Silverman, Lewis B, Harris, Marian H, Stevenson, Kristen E, Weinstock, David M, Weng, Andrew P, Van Vlierberghe, Pieter, D’Andrea, Alan D, and Gutierrez, Alejandro
- Subjects
Biological Sciences ,Biomedical and Clinical Sciences ,Genetics ,Oncology and Carcinogenesis ,Hematology ,Pediatric Cancer ,Orphan Drug ,Pediatric ,Childhood Leukemia ,Pediatric Research Initiative ,Cancer ,Rare Diseases ,Human Genome ,Aetiology ,2.1 Biological and endogenous factors ,Animals ,BRCA2 Protein ,Cell Line ,Tumor ,Child ,Fanconi Anemia Complementation Group D2 Protein ,Genes ,BRCA1 ,Genes ,BRCA2 ,Haploinsufficiency ,Heterografts ,Humans ,Jurkat Cells ,Male ,Mice ,Mice ,Inbred NOD ,Mutagenesis ,Site-Directed ,Mutation ,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ,Radiation Tolerance ,Sequence Analysis ,DNA ,Sequence Analysis ,RNA ,Ultraviolet Rays ,General Science & Technology - Abstract
BRCA2 (also known as FANCD1) is a core component of the Fanconi pathway and suppresses transformation of immature T-cells in mice. However, the contribution of Fanconi-BRCA pathway deficiency to human T-cell acute lymphoblastic leukemia (T-ALL) remains undefined. We identified point mutations in 9 (23%) of 40 human T-ALL cases analyzed, with variant allele fractions consistent with heterozygous mutations early in tumor evolution. Two of these mutations were present in remission bone marrow specimens, suggesting germline alterations. BRCA2 was the most commonly mutated gene. The identified Fanconi-BRCA mutations encode hypomorphic or null alleles, as evidenced by their inability to fully rescue Fanconi-deficient cells from chromosome breakage, cytotoxicity and/or G2/M arrest upon treatment with DNA cross-linking agents. Disabling the tumor suppressor activity of the Fanconi-BRCA pathway is generally thought to require biallelic gene mutations. However, all mutations identified were monoallelic, and most cases appeared to retain expression of the wild-type allele. Using isogenic T-ALL cells, we found that BRCA2 haploinsufficiency induces selective hypersensitivity to ATR inhibition, in vitro and in vivo. These findings implicate Fanconi-BRCA pathway haploinsufficiency in the molecular pathogenesis of T-ALL, and provide a therapeutic rationale for inhibition of ATR or other druggable effectors of homologous recombination.
- Published
- 2019